Product Description
Camostat is an orally bioavailable, synthetic serine protease inhibitor, with anti-inflammatory, antifibrotic, and potential antiviral activities. Upon oral administration, camostat and its metabolite 4-(4-guanidinobenzoyloxyl)phenyl acetic acid (FOY 251) inhibit the activities of a variety of proteases, including trypsin, kallikrein, thrombin and plasmin, and C1r- and C1 esterases. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Camostat)
Mechanisms of Action: SP Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: India | Korea | Philippines
Approved Indications: None
Known Adverse Events: None
Company: ONO Pharm
Company Location: CHUO-KU OSAKA 541 JA M0
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: COVID-19
Phase 3: Severe Acute Respiratory Syndrome|COVID-19|Communicable Diseases
Phase 2: COVID-19|Communicable Diseases|Cystic Fibrosis|Hypertension|Obesity|Severe Acute Respiratory Syndrome|Respiratory Tract Infections|Kidney Diseases|Proteinuria
Phase 1: COVID-19|Communicable Diseases|Severe Acute Respiratory Syndrome|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2023-508516-34-00 | P2 |
Unknown Status |
Kidney Diseases|Proteinuria |
2025-12-31 |
|
| DAWN | P3 |
Terminated |
Severe Acute Respiratory Syndrome|COVID-19 |
2022-07-13 |
|
| COV-AAT | P2 |
Terminated |
COVID-19 |
2022-07-12 |
|
| SPIKE-1 | P3 |
Unknown status |
COVID-19 |
2022-06-18 |